Jump to content

ESHAP

From Wikipedia, the free encyclopedia

ESHAP is an acronym for relatively intensive chemotherapy regimen that is used for salvage therapy in relapsed or refractory lymphomas and Hodgkin's lymphoma. In combination with monoclonal antibody Rituximab it is called R-ESHAP or ESHAP-R.[1]

R-ESHAP consists of:

  1. Rituximab, an anti-CD20-directed monoclonal antibody that kills both normal and malignant B-lymphocytes
  2. Etoposide, an epipodophyllotoxin topoisomerase inhibitor
  3. Solu-Medrol - Methylprednisolone, which is a glucocorticoid that can lyse lymphocytes
  4. High-dose Ara-C - cytarabine
  5. Platinol - Cisplatin, a platinum-based antineoplastic agent, also an alkylating antineoplastic agent.

Dosing regimen

[edit]
Drug Dose Mode Days
Rituximab 375 mg/m2 IV infusion Day 0
Etoposide 40 mg/m2 IV infusion over 1 hr Days 1-4
Solu-Medrol - Methylprednisolone 500 mg IV bolus over 15 min Days 1-5
High-dose Ara-Ccytarabine 2000 mg/m2 IV infusion over 2 hrs Day 5
Platinol (cisplatin) 25 mg/m2 IV continuous infusion over 24 hrs Days 1-4

References

[edit]